Uveitis Long Term Trial And Diabetic Macular Edema Trial Results Positive For pSivida Limited

PERTH, Australia & BOSTON--(BUSINESS WIRE)--Feb. 21, 2006--Global bio-nanotech company pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced that preliminary three year follow-up data from Bausch and Lomb’s multi-center, randomized, dose-masked clinical trial of Retisert(TM) for the treatment of chronic non-infectious posterior segment uveitis has been published. Global eye health company, Bausch and Lomb (NYSE:BOL), exclusive licensee of Retisert(TM), conducted the study that showed the recurrence rate was significantly lower in eyes receiving Retisert(TM) than in non-implanted eyes. This study involved 278 patients from 27 hospitals in the United States and one in Singapore.